readthroughSign in
Nov 13, 2026Quarterly update

Curis updates on emavusertib trials in CLL and PCNSL, flags tight cash runway

Curis reported 12 patients enrolled in its TakeAim CLL study with initial data expected in December 2026, while warning it lacks cash to fund operations for the next 12 months.

Curis, Inc. reported third quarter 2026 results on November 12, 2026, and gave updates on its two lead studies of emavusertib, an oral IRAK4 and FLT3 inhibitor. The company is enrolling patients in two ongoing studies, the TakeAim CLL study and the TakeAim Lymphoma study in PCNSL.1

In the TakeAim CLL study, an open label Phase 2 trial combining emavusertib with zanubrutinib, eligible participants must have received zanubrutinib for at least 12 months, achieved a partial response or partial response with lymphocytosis, and have measurable residual disease as determined by the clonoSEQ assay.1 As of the update, 12 patients had been enrolled, with initial data expected in December 2026.1

For the TakeAim Lymphoma study, a registrational trial combining emavusertib with ibrutinib in relapsed or refractory PCNSL, Curis said that in 2025 it presented initial clinical data to the FDA and EMA's CHMP and received feedback indicating the ongoing study could support applications for accelerated approval.1 As of July 1, 2026, the company reported data on 7 BTK-naïve and 39 BTKi-experienced patients, with evaluable BTKi-naïve patients showing a 100% objective response rate (5 of 5) and BTKi-experienced evaluable patients showing a 33% objective response rate (10 of 30).1

On financing, Curis said it completed a public stock offering in August 2026 and a private placement in October 2026, which it said extended its cash runway into 2027.1 Cash and cash equivalents totaled $5.0 million as of September 30, 2026, with about 4.1 million shares outstanding.1 The company said that cash, together with roughly $7.5 million in net proceeds from the October 2026 private placement, should fund operations into the first quarter of 2027.1 Despite that statement, the filing's risk disclosure said based on available cash resources, the company does not have sufficient cash on hand to support current operations within the next 12 months from the date of the release.1

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.